MSFrontier

Being tested

S1P receptor modulation (lymphocyte trafficking): reduce relapses and new lesions in relapsing MS

Trial timeline

Phase 320052014
Phase 2/320122012

Trial start year. Dot size reflects participants where reported. Only trials that count towards the status are shown.

relapsing MS · S1P receptor modulation (lymphocyte trafficking)

Trials are running now and no controlled trial has a readable result yet.

Trials
33
Running now
5
Controlled phase 2/3 trials
16
People in controlled trials
10683

Deciding trials (phase 3): 7 met, 0 did not.

Other linked trials: 26

Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.

Trials

  • SUNBEAMdecides the statusMet main goal

    Phase 3 · 2014 · Compared with interferon beta-1a · MSFT-NCT02294058

  • Safety and Efficacy of Fingolimod in MS Patients in Chinadecides the statusStopped, other reason

    Phase 3 · 2014 · Placebo-controlled · MSFT-NCT01941004

  • RADIANCEdecides the statusMet main goal

    Phase 3 · 2013 · Compared with interferon beta-1a · MSFT-NCT02047734

  • CFTY720D2311decides the statusMet main goal

    Phase 3 · 2013 · Compared with interferon beta-1a · MSFT-NCT01892722

  • ASSESSdecides the statusMet main goal

    Phase 3 · 2012 · Compared with glatiramer acetate · MSFT-NCT01633112

    Treatment with fingolimod, 0.5 mg, was superior to treatment with glatiramer acetate, 20 mg, in reducing ARR (40.7% relative reduction); the relative reduction with fingolimod, 0.25 mg, was 14.6%, which was not statistically significant (for fingolimod, 0.5 mg, ARR, 0.15; 95% CI, 0.11-0.21; for fingolimod, 0.25 mg, ARR, 0.22; 95% CI, 0.17-0.29; for glatiramer acetate, 20 mg, ARR, 0.26; 95% CI, 0.20-0.34).

    Read by software from the paper's abstract
  • TOFIINGOdecides the statusStopped, other reason

    Phase 3 · 2011 · Placebo-controlled · MSFT-NCT01499667

  • N/Adecides the statusNo result found

    Phase 3 · 2008 · Placebo-controlled · MSFT-2008-002096-27

  • FREEDOMS IIdecides the statusMet main goal

    Phase 3 · 2006 · Placebo-controlled · MSFT-NCT00355134

    Mean annualised relapse rate was 0·40 (95% CI 0·34-0·48) in patients given placebo and 0·21 (0·17-0·25) in patients given fingolimod 0·5 mg: rate ratio 0·52 (95% CI 0·40-0·66; p<0·0001), corresponding to a reduction of 48% with fingolimod 0·5 mg versus placebo.

    Read by software from the paper's abstract
  • FREEDOMSdecides the statusMet main goal

    Phase 3 · 2006 · Placebo-controlled · MSFT-NCT00289978

    The annualized relapse rate was 0.18 with 0.5 mg of fingolimod, 0.16 with 1.25 mg of fingolimod, and 0.40 with placebo (P<0.001 for either dose vs. placebo).

    Read by software from the paper's abstract
  • D2301decides the statusNo result found

    Phase 3 · 2005 · Placebo-controlled · MSFT-2005-000365-19

Other linked trials: 26

These linked trials do not set the status.

The deciding phase and counts come from the Trial Bank’s fixed rules.

Lab evidence

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Loading reviews and guidelines…

History

  • 2026-10-29Trials: 31 → 33
  • 2026-10-28Trials: 33 → 31
  • 2026-10-27First listed as Being tested

Related hypotheses

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error